FamiCord Expanded Access Protocol

FamiCord Expanded Access Protocol : A Breakthrough In The Use of The Own Stem Cells

FamiCord Group has launched a treatment program to help FamiCord clients to use autologous cord blood stem cells for the treatment of cerebral palsy and autism spectrum disorder. This initiative ensures that FamiCord Group clients from across Europe can access innovative stem cell therapies already being conducted in Poland. The University Children’s Hospital in Lublin is the partner of FamiCord Group in this project.

The program, known as the FamiCord Group Expanded Access Protocol for Cord Blood in Brain Development, represents a significant opportunity for children suffering from these conditions, particularly cerebral palsy, as autologous (own) cord blood infusion presents a potential path for clinical improvement. The foundation for launching the program was the results of clinical trials led by Professor Joanne Kurtzberg and conducted at the Duke University in the United States, which demonstrated clinical benefits achieved by children with cerebral palsy after receiving their own cord blood. Regarding the use of cord blood in autism spectrum disorder (ASD), there are also clinical benefits; research has shown that these benefits are more pronounced in children without intellectual disabilities. It has been also confirmed that clinical benefit was achieved when appropriate dose of cells was infused. Procedure is safe and well tolerated.

The program is aimed at clients of FamiCord Group who have their own cord blood stored in the group’s laboratories and have a diagnosis of autism spectrum disorder (ASD) or cerebral palsy (CP). Additionally, the cord blood unit must meet strict qualification criteria to ensure its suitability for treatment. This targeted approach ensures that eligible patients have access to potentially life-changing therapies using their own stem cells.

The primary physician responsible for the programme Is Professor Magdalena Chrościńska-Krawczyk, MD, PhD, she is a paediatric neurologist at University Children’s Hospital in Lublin.

For FamiCord Group clients, who wants to use their own cord blood for treatment, FamiCord Group launched the dedicated email: braindevelopment@pbkm.pl. So, if you are one of our clients – don’t hesitate to contact us.

You can access the leaflet here https://famicord.com/wp-content/uploads/2025/01/eksperyment-segregator-EN-04-10-2019_prev-3.pdf

Disclaimer: Famicord cannot guarantee that you will be accepted to participate in the programme. Famicord reserves the right to stop.